- Conditions
- Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma
- Interventions
- Abiraterone Acetate, Androgen Receptor Antagonist ARN-509, Gonadotropin-releasing Hormone Analog, Prednisone, Quality-of-Life Assessment, Questionnaire Administration, Radical Prostatectomy
- Drug · Biological · Other + 1 more
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- Male only
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • New Brunswick, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 241–241
of 241
matching trials from the live ClinicalTrials.gov search.